Intranasal Neurostimulation for the Treatment of Neurosensory Abnormalities in CL Wearers (INTAC)

Inclusion Criteria: * At least 21 years of age at screening visit * Ocular Surface Disease Index (OSDI) score of less than 12 (without contact lens wear) * Contact Lens Dry Eye Questionnaire (CLDEQ)-8 score of greater than 12.18 * Regular contact lens wearer who wears them less than 6 hours per day due to discomfort * The presence of at least one microneuroma on in vivo confocal microscopy * Self-reported good compliance with healthy contact lens regimen (replace contact lenses per manufacturer's recommendations, use of multipurpose or hydrogen peroxide contact lens solution nightly) * Have had an eye exam within the last two years that included dispense of a contact lens prescription * Proparacaine drops relieve at least 75% of ocular symptoms to ensure that patients do not have centralized neuropathic corneal pain * If a soft lens wearer, use a contact lens that was released within the last 15 years Exclusion Criteria: * Use of topical drops other than artificial tear substitutes * Ocular surgery or other ocular disease within 3 months prior to study enrollment * Concurrent ocular disease that may impact results * Have dry eye (as defined by 2 or more of the parameters below) * Schirmer's wetting test \< 10mm * TBUT \<7sec * NEI scale corneal staining of 4 out of 15 at the time of enrollment * Improper CL fit * No microneuroma by in vivo confocal microscopy * Overnight wear within 1 month of screening visit * Use of colored or cosmetic lenses * Contra-indication to ITN * Chronic or recurrent epistaxis, coagulation disorders. * Nasal or sinus surgery or significant trauma to the nose. * Cardiac demand pacemaker, implanted defibrillator, or other implanted electronic device in the head or neck. * Chronic or recurrent nosebleeds * Bleeding disorder * Known hypersensitivity (allergy) to the hydrogel material * Disabling arthritis, neuropathy, or limited motor coordination affecting self-handling of the device. * History of migraines * Under 21 years of age